HomeAI · summaries
Storia in 7 fonti
Regeneron's Pasatru scores FDA approval in ultrarare bone lesions disorder
After more than 10 years in development, Regeneron secured a landmark approval for its monoclonal antibody garetosmab, now commercially known as Pasatru. | Regeneron's Pasatru has crossed the finish line with an FDA approval after more than ten years in development. The drug is only the second approved treatment for FOP, an ultrarare genetic condition that causes patients' soft tissues to turn to bone.
Confronto fonti
6 prospettive sulla stessa storiaTimeline cronologica
- ·
medpagetoday.com
FDA Approves Activin Signaling Inhibitor for Bone Disorder
Ultra-rare fibrodysplasia ossificans progressiva now has its second approved drug
- ·
statnews.com
Regeneron drug for disease that causes dangerous bone growth earns FDA approval
A Regeneron drug that treats an ultra-rare disease that causes bone to form where it's not meant to be has won approval.
